Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-003306
Filing Date
2025-02-06
Accepted
2025-02-06 21:09:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8668
  Complete submission text file 0001415889-25-003306.txt   10405
Mailing Address SCHERFIGSVEJ 7 COPENHAGEN G7 DK-2100
Business Address SCHERFIGSVEJ 7 COPENHAGEN G7 DK-2100 4540307375
Lundbeckfond Invest A/S (Filed by) CIK: 0001591046 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Subject) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92480 | Film No.: 25598990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)